Free Trial
NASDAQ:SKYE

Skye Bioscience Q2 2026 Earnings Results & Report

Skye Bioscience logo
$1.09 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.16 +0.07 (+6.06%)
As of 11/13/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Skye Bioscience beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.27 versus the -$0.29 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Skye Bioscience EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Skye Bioscience Q2 2026 Earnings FAQ

Skye Bioscience (NASDAQ:SKYE) reported earnings of -$0.27 per share for Q2 2026, beating the consensus estimate of -$0.29. The report was announced on Friday, August 14, 2026.

Skye Bioscience Earnings Headlines

Skye Bioscience (NASDAQ:SKYE) Stock Price Down 4.8% - Here's Why
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company developing medicines that target the endocannabinoid system. Its research focuses on cannabinoid receptor 1 (CB1), which is involved in metabolic and other physiological processes.

The company’s lead program is nimacimab, an antibody designed to inhibit CB1 activity outside the brain. Skye is investigating the candidate as a potential treatment for obesity and related metabolic conditions.

Skye has also developed SBI-100 ophthalmic emulsion, an experimental eye treatment studied for glaucoma and ocular hypertension. The company is based in San Diego, California, and has shifted its development focus toward nimacimab.

View Skye Bioscience Profile